기자가 쓴 기사 더보기
(편집자 주 - 글로벌 제약기업인 애보트 (Abbott) 미국법인은 9월 23일 "자사의 씨밀락 (Similac) 제품에 위장장애와 소화불량 등을 불러 일으킬 수 있는 벌레나 유충이 들어가 있다"며 "리콜에 돌입한다"고 밝혔습니다.)
AUDIENCE: Consumer, Pediatrics
ISSUE: Possibility of the presence of a small common beetle in the product.
The FDA has determined that while the formula containing these beetles poses no immediate health risk, there is a possibility that infants who consume formula containing the beetles or their larvae, could experience symptoms of gastrointestinal discomfort and refusal to eat as a result of small insect parts irritating the GI tract.
BACKGROUND: The recall of these powder infant formulas includes certain Similac powder product lines offered in plastic containers, and certain Similac powder product lines offered in sizes such as 8-ounce, 12.4-ounce and 12.9-ounce cans. See the Product Photo page.
The recall includes powder infant formulas sold in the U.S., Puerto Rico, Guam and some countries in the Caribbean. No Abbott liquid infant formulas are impacted.
RECOMMENDATION: If symptoms are noted and persist for more than a few days, a physician should be consulted.
Products with affected lot numbers should be returned to Abbott at no cost to the consumer.
To immediately find out if the product in your possession is included in this recall, parents and caregivers should visit www.similac.com/recall , and type in their lot number to determine if their product is affected, or call (800) 986-8850.
| 인기기사 | 더보기 + |
| 1 | [2월 4주] 한미 경영권 '승부수' 띄운 신동국… 알테오젠·제일·신풍은 실적 '활짝' |
| 2 | [DIA CGT 서밋] 코아스템켐온 “빠른 혁신, 느린 적용…상용화 병목 해결해야” |
| 3 | 네이처셀, 조인트스템 미국 FDA 허가 추진 현황 등 설명 |
| 4 | 카나프테라퓨틱스,공모가 상단 2만원 확정…경쟁률 962.1대 1 |
| 5 | 알지노믹스, AACR서 간암 유전자치료제 ‘RZ-001’ 임상 중간결과 구두 발표 |
| 6 | 셀트리온, 자사주 소각 규모 911만주로 확대..총 2조원 육박 규모 |
| 7 | 보건의료 난제 풀 ‘한국형 ARPA-H’, 2026년 9개 신규 R&D 띄운다 |
| 8 | 바이오플러스,'살아있는 인간 유전자'로 만든 콜라겐 상용화 성공 |
| 9 | 조두연 사장 "디티앤씨알오 임상사업부 대전환…‘운영’에서 ‘전략 CRO'" |
| 10 | 덴티스 'AXEL' 美 FDA 승인…프리미엄 임플란트 시장 공략 |
| 인터뷰 | 더보기 + |
| PEOPLE | 더보기 + |
| 컬쳐/클래시그널 | 더보기 + |
(편집자 주 - 글로벌 제약기업인 애보트 (Abbott) 미국법인은 9월 23일 "자사의 씨밀락 (Similac) 제품에 위장장애와 소화불량 등을 불러 일으킬 수 있는 벌레나 유충이 들어가 있다"며 "리콜에 돌입한다"고 밝혔습니다.)
AUDIENCE: Consumer, Pediatrics
ISSUE: Possibility of the presence of a small common beetle in the product.
The FDA has determined that while the formula containing these beetles poses no immediate health risk, there is a possibility that infants who consume formula containing the beetles or their larvae, could experience symptoms of gastrointestinal discomfort and refusal to eat as a result of small insect parts irritating the GI tract.
BACKGROUND: The recall of these powder infant formulas includes certain Similac powder product lines offered in plastic containers, and certain Similac powder product lines offered in sizes such as 8-ounce, 12.4-ounce and 12.9-ounce cans. See the Product Photo page.
The recall includes powder infant formulas sold in the U.S., Puerto Rico, Guam and some countries in the Caribbean. No Abbott liquid infant formulas are impacted.
RECOMMENDATION: If symptoms are noted and persist for more than a few days, a physician should be consulted.
Products with affected lot numbers should be returned to Abbott at no cost to the consumer.
To immediately find out if the product in your possession is included in this recall, parents and caregivers should visit www.similac.com/recall , and type in their lot number to determine if their product is affected, or call (800) 986-8850.